Decades of research link lithium deficiency to Alzheimer's, yet it's ignored in favor of expensive, ineffective drugs like Aduhelm.
The medical-industrial complex suppresses lithium because it's unpatentable and threatens Big Pharma's lucrative, failing treatments.
Low-dose lithium orotate enhances cognition, prevents neurodegeneration and stabilizes mood—without the toxicity of high-dose prescriptions.
True brain health requires rejecting pharma-controlled medicine, detoxing from toxins and embracing natural, repurposed therapies like lithium.
For decades, lithium has been pigeonholed as merely a psychiatric drug—prescribed in high doses by mainstream medicine to manage bipolar disorder while ignoring its far broader potential. But emerging research suggests this humble mineral may hold the key to preventing neurodegenerative diseases like Alzheimer's, offering a natural, low-cost solution that threatens the pharmaceutical industry's profit-driven stranglehold on brain health.
Dr. David Fajgenbaum, a physician-scientist and survivor of a rare immune disease, has become a leading advocate for drug repurposing—the practice of uncovering new uses for existing, often overlooked treatments. His work exposes a critical flaw in modern medicine: the system is rigged to prioritize expensive, patented drugs while ignoring safe, effective and affordable alternatives like lithium....<<<Read More>>>...
